Cardiac toxicity in breast cancer patients treated with dual HER2 blockade

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2245-2252

  Valachis, Antonis ^a,b   Nearchou, Andreas ^a   Polyzos, Nikolaos P ^c   Lind, Pehr ^a,d  

^a Department of Oncology ^*  (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

breast cancer; cardiotoxicity; dual HER2 blockade; Her2; meta analysis

Indexed keywords

LAPATINIB; PERTUZUMAB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DRUG SAFETY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW;

BREAST CANCER; CARDIOTOXICITY; DUAL HER2 BLOCKADE; HER2; META-ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84882674891     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28234     Document Type: Article

References (24)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
2. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-8.
3. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
4. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
5. Martín M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14: 1-11.
6. Perez EA, Byrne JA, Isaac W, et al. Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol 2006; 17 (suppl 9): ix70.
7. Zha o YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261-10269.
8. De Keulenaer GW, Doggen K, Lemmens K,. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted erbb2 anticancer therapy. Circ Res 2010; 106: 35-46.
9. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: fina results from the EGF104900 Study. J Clin Oncol 2012; 30: 585-92.
10. Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30: 1989-95.
11. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-40.
12. Robidoux A, Tang G, Rastogi P, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2? operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012; (suppl; abstr LBA506).
13. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
14. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
15. Lenihan D, Suter T, Brammer M, et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012; 23: 791-800.
16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
17. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias I randomised trials. BMJ 2011; 343: d5928.
18. Sweeting MJ, Sutton AJ, Lambert PC,. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351-75.
19. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28: 3416-21.
20. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28: 3422-8.
21. de Azambuja E, Bedard PL, Suter T, et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 2009; 4: 77-88.
22. Sutton AJ, Cooper NJ, Lambert PC, et al. Meta-analysis of rare and adverse event data. Expert Rev Pharmacoecon Outcomes Res 2002; 2: 367-79.
23. Tomasello G, de Azambuja E, Dinh P, et al. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2008; 8: 1883-90.
24. von Minckwitz G, Baselga J, Bradbury I, et al. Adjuvant Pertuzumab and HerceptIN iniTial TherapY of breast cancer: APHINITY (BIG 4-11/BO25126/TOC439g). Cancer Res 2011; 71: 602 (OT1-02-04).